
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.
GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...





